基于益生菌的自我交叉连接生物涂层用于治疗大肠炎,通过增加益生菌殖民的方法来治疗大肠炎
Shang Shi1,2, Boqing Li2, Ying Zhang2
1Department of Microbiology, College of Life Sciences, Shandong Agricultural University, Taian, 271018, China.
Materials today. Bio
|November 10, 2025
概括
使用粘性蛋白 (Map) 和酸盐 (Alg) 的新型生物涂层策略显著提高益生菌的存活率和殖民性,用于治疗炎症性肠病 (IBD). 这种改善的益生菌输送恢复了肠道屏障功能,并调节了小鼠的肠道微生物群.
科学领域:
- 生物材料科学 生物材料科学
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 益生菌疗法对炎症性肠病 (IBD) 有希望,但面临着生存和在胃肠道中向输送的挑战.
- 开发有效的输送系统对于克服恶劣的胃肠道环境和提高IBD治疗益生菌疗效至关重要.
研究的目的:
- 开发和评估一种生物涂层益生菌配方,BL@Map@Alg,以提高大肠炎小鼠模型中的生存,殖民和治疗效果.
- 研究生物涂层对益生菌对环境压力因素的耐药性及其恢复肠道屏障功能和调节肠道微生物群的能力的影响.
主要方法:
- BL@Map@Alg的配方使用自我交叉连接的贝类粘合蛋白 (Map) 和酸 (Alg) 进行涂层 *Bifidobacterium longum* (BL).
- 在氧气暴露和模拟胃酸下评估BL@Map@Alg生存率,并评估小鼠的肠道殖民.
- 用BL@Map@Alg给DSS诱导的小鼠结肠炎模型,然后通过16SrRNA测序分析体重减轻,结肠长度,炎症性细胞因子,紧结蛋白 (ZO-1,Claudin-1),以及肠道微生物群组成.
主要成果:
- BL@Map@Alg显著提高了生存率 (增加了19.6倍,而不是氧气下未涂层的BL) 和对胃酸的耐药性 (增加了76.8倍).
- 该配方实现了肠道殖民的6.2倍增加和卓越的ROS清理能力,将ROS水平降低了41.1%.
- 在大肠炎模型中,BL@Map@Alg减少了疾病的严重程度,通过增加ZO-1和Claudin-1水平恢复了肠道屏障功能,并通过减少*Escherichia*和增加*Akkermansia*丰富度,有利地改变了肠道微生物群.
结论:
- 贝粘合蛋白-藻酸生物涂层有效地保护益生菌,增强它们的生存,殖民和治疗炎症性肠道疾病的疗效.
- BL@Map@Alg代表了精准医学的一个有前途的战略,为IBD治疗提供了改善的益生菌输送和肠道微生物群调节.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
186
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
186
01:29Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
01:29Inflammatory Bowel Disease IV: Pharmacological Management
459
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
459
01:21Drugs for Treatment of Constipation-Predominant IBS
686
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
686